| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 19% YoY growth to ₹698 Cr, driven by volume and exports. |
|---|---|
| Margins | EBITDA margin at 12.5%, up 91 bps sequentially due to mix. |
| Demand visibility | Strong export demand; domestic customers remain cautious due to volatility. |
| Management confidence | Balanced; optimistic on long-term strategy but cautious regarding global logistics. |
Growth
Revenue grew 19% YoY to ₹698 Cr, driven by HPPC and Textile segments, with significant volume-led export expansion.
Outlook
Targets 30%+ export revenue contribution by year-end; guides EBITDA margins around 12% for FY27.
Risks
Logistical costs (Red Sea) and Ethylene Oxide supply constraints pose margin pressures.
Earnings Call Transcript filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹410.80
- Market cap
- ₹2,276 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 14.9×Sector 34.5×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech reported record quarterly revenue of Rs. 697.6 Cr (up 19% YoY) and EBITDA of Rs. 87 Cr (up 21% YoY). Performance driven by volume and product mix.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth